Details of the Drug Reposition

General Information of This Drug (ID: DMJV2EK)

Drug Name
Dasatinib   DMJV2EK
Synonyms
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive DIS3KLUX N.A. Approved [1]
Glioblastoma DISI0V5E 2A00 Approved [1]
Chronic myelogenous leukaemia DIS0301E 2A20.0 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Central nervous system disease DISFB8P5 8A04-8D87 Approved [1]
Brain disease DIS6ZC3X 8C70-8E61 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia, myeloid, accelerated-phase DISNDQL5 N.A. Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Investigative [3]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Investigative [3]
------------------------------------------------------------------------------------

References

1 Dasatinib FDA Label
2 Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
3 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.